Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer

Osimertinib has become a standard of care in the first-line treatment of advanced-stage non-small-cell lung cancer (NSCLC) harboring exon 19 and 21 activating mutations in the EGFR gene. Nevertheless, the 18.9-month median progression-free survival emphasizes the fact that resistance to osimertinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Aboubakar Nana, Frank, Ocak, Sebahat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471192/
https://www.ncbi.nlm.nih.gov/pubmed/34575554
http://dx.doi.org/10.3390/pharmaceutics13091478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471192/
https://www.ncbi.nlm.nih.gov/pubmed/34575554
http://dx.doi.org/10.3390/pharmaceutics13091478

Ejemplares similares